The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast “ALN-PCSsc for the Treatment of Hypercholesterolemia”
The Medicines Company (NASDAQ:MDCO) today announced that in collaboration with Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be hosting the “ALN-PCSsc for the treatment of Hypercholesterolemia” RNAi Roundtable webcast on August 14, 2014. Event details are below.
RNAi Roundtable webcast: “ALN-PCSsc for the treatment of Hypercholesterolemia” Thursday, August 14 @ 4:00 p.m. - 5:00 p.m. ET
- Kevin Fitzgerald, Ph.D., Senior Director, Research, Alnylam Pharmaceuticals
- David Kallend, MBBS, Vice President and Global Medical Director, The Medicines Company
- Moderator: Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer, Alnylam Pharmaceuticals
- Guest Speaker: Christie Ballantyne, M.D., Professor of Medicine, Physiology, and Molecular and Human Genetics, and Chief, Department of Medicine, Sections of Cardiology and Cardiovascular Research at Baylor College of Medicine
The event will be webcast live on the Investors section of Alnylam’s website, www.alnylam.com. The event can be accessed through The Medicines Company’s website in the Investors section at www.themedcinescompany.com. An audio replay of the roundtable will be posted on the Alnylam website approximately three hours after the event.
About The Medicines Company
The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.
The Medicines Company
Neera Dahiya Ravindran, MD, +1-973-290-6044
Vice President, Investor Relations & Strategic Planning
Cynthia Clayton, +1-617-551-8207
Vice President, Investor Relations & Corporate Communications